TriSalus jumps after FDA clears liver treatment device
TLSI•Shares rise after FDA clearance
-
Shares of cancer therapy firm TriSalus TLSI.O rise 7.5% to $5.3
-
Co receives FDA clearance for its Trinav Advance device, expanding its product portfolio delivering targeted treatments to the liver
-
Co plans a limited market release of the device in the coming weeks
-
Five brokerages rate the stock "buy"; median PT is $9 - data compiled by LSEG
-
Including session's move, stocks down 29.4% YTD
